Lemalesomab
Monoclonal antibody
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Lemalesomab is a mouse monoclonal antibody for the diagnosis of inflammatory lesions.[1][2]
References
- ^ "International Nonproprietary Names (INN) for Pharmaceutical Substances Proposed INN: List 84" (PDF). WHO Drug Information. 14 (4): 260. 2000.
- ^ Pelletier JP (2020). "Chapter 16 - Passive Monoclonal and Polyclonal Antibody Therapies". In Maitta RW (ed.). Immunologic concepts in transfusion medicine. Philadelphia: Elsevier. p. 296. doi:10.1016/B978-0-323-67509-3.00016-0. ISBN 978-0-323-67510-9. S2CID 213508934.
- v
- t
- e
Monoclonal antibodies for the immune system
Human | |
---|---|
Humanized | |
Veterinary |
Mouse |
|
---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
![]() | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e